Lamins are the type-V intermediate filaments that build the nuclear lamina — the meshwork lining the inner nuclear membrane that gives the nucleus its shape and shock-absorption, anchors chromatin and pore complexes, and links the genome to the cytoskeleton through LINC complexes. B-type lamins (B1, B2) are everywhere and essential; A-type lamins (A and C, from one LMNA gene) appear as tissues differentiate and bear the astonishing spectrum of "laminopathies": Hutchinson-Gilford progeria (premature aging), Emery-Dreifuss muscular dystrophy, dilated cardiomyopathy, lipodystrophy, and neuropathy — one gene, eight tissues, eight diseases of the nucleus.
Gene
LMNA (A/C), LMNB1, LMNB2
Family
Type V intermediate filament proteins
Location
Nuclear lamina (inner nuclear membrane)
Structure
~570–660 aa rod + Ig-fold tail; CAAX-farnesylated lamin A processed to mature form
Binding Partners
LAP2, emerin, lamin B receptor, histones, nesprins (LINC)
Structure
Like all intermediate filaments, a coiled-coil rod with head and tail; the C-terminal Ig-like domain binds chromatin and partner proteins.
Prelamin A's farnesyl tail is normally clipped off (by ZMPSTE24); progeria's mutation deletes the cleavage site, leaving a permanently farnesylated, progerin molecule that distorts the lamina.
Lamin C skips the CAAX processing entirely — alternative splicing of the same LMNA transcript.
Function
Nuclear architecture: the lamina is the nucleus' shock absorber and shape-setter — lamin-A-rich tissues (muscle, bone) are stiff-tissue matched by stiff lamina.
Genome organisation: lamina-associated domains (LADs) hold silent chromatin at the periphery — lamins are epigenetic geography, not just structure.
Mechano-transduction: through LINC complexes and nesprins, lamins connect the cytoskeleton to the nuclear interior — the path by which matrix stiffness changes gene expression.
Regulation
Lamina disassembly and reassembly round mitosis: CDK1 phosphorylation dissolves the meshwork, phosphatases rebuild it around the daughter nuclei.
Lamin A expression scales with tissue stiffness and mechanical load — the differentiation marker that mesenchymal stiffening induces.
Processing steps (farnesylation, ZMPSTE24 cleavage) are checkpoints — their genetic failure defines the progeroid syndromes.
Interactions
Emerin and the LINC complex bridge lamins to the cytoskeleton — Emery-Dreifuss dystrophy can be caused by LMNA or emerin alike, the same module broken twice.
With vimentin: perinuclear intermediate-filament coupling in migrating cells.
With p53 and cell-cycle checkpoints: progerin's disturbed lamina activates p53-dependent senescence — aging's cellular readout through senescence.
Clinical Relevance
Laminopathies: Hutchinson-Gilford progeria (G608G progerin), LMNA muscular dystrophies and the cardiomyopathy-conduction cluster, familial partial lipodystrophy, Charcot-Marie-Tooth type 2B1 — genotype-tissue puzzles still being solved.
Therapy: lonafarnib (farnesyltransferase inhibitor) slows progeria — the first approved treatment, aimed at the processing defect.
Aging biology: progerin accumulates in normal aging vasculature — the lamina as a clock of somatic wear — see genome maintenance's wider story.